Free Trial
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

$15.06
-0.42 (-2.71%)
(As of 11:02 AM ET)
Today's Range
$15.06
$15.67
50-Day Range
$13.84
$17.55
52-Week Range
$12.95
$25.47
Volume
58,313 shs
Average Volume
769,010 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.11

Arcus Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
148.1% Upside
$38.11 Price Target
Short Interest
Healthy
12.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Arcus Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.07) to ($3.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

327th out of 915 stocks

Pharmaceutical Preparations Industry

150th out of 435 stocks

RCUS stock logo

About Arcus Biosciences Stock (NYSE:RCUS)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Stock Price History

RCUS Stock News Headlines

Arcus Biosciences (NYSE:RCUS) Price Target Cut to $25.00
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/17/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.11
High Stock Price Target
$70.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+146.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-307,000,000.00
Pretax Margin
-95.78%

Debt

Sales & Book Value

Annual Sales
$117 million
Book Value
$6.17 per share

Miscellaneous

Free Float
79,766,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
0.90
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Terry J. Rosen Ph.D. (Age 64)
    Co-Founder, Chairman & CEO
    Comp: $756.11k
  • Dr. Juan Carlos Jaen Ph.D. (Age 66)
    Co- Founder & President
    Comp: $931.14k
  • Mr. Robert C. Goeltz IIMr. Robert C. Goeltz II (Age 51)
    Principal Financial Officer & CFO
    Comp: $745.29k
  • Ms. Jennifer A. Jarrett M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $925.29k
  • Dr. Dimitry S.A. Nuyten M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700.34k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Alexander Azoy (Age 48)
    VP of Finance & Principal Accounting Officer
  • Dr. Jonathan Yingling Ph.D. (Age 55)
    Chief Scientific Officer

RCUS Stock Analysis - Frequently Asked Questions

How have RCUS shares performed this year?

Arcus Biosciences' stock was trading at $19.10 at the beginning of 2024. Since then, RCUS shares have decreased by 19.6% and is now trading at $15.36.
View the best growth stocks for 2024 here
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Wednesday, May, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.92. The firm's quarterly revenue was up 480.0% on a year-over-year basis.

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Arcus Biosciences IPO?

Arcus Biosciences (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' top institutional investors include SG Americas Securities LLC (0.14%) and Diversified Trust Co (0.01%). Insiders that own company stock include Gilead Sciences, Inc, Juan C Jaen, Terry J Rosen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang and Alexander Azoy.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Arcus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Gilead Sciences (GILD).

This page (NYSE:RCUS) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners